Annals of pancreatic cancer最新文献

Background: Bibliometric review offers a comprehensive and quantitative evaluation of pancreatic cancer research, focusing on journal and author productivity. Despite significant efforts to improve pancreatic cancer outcomes and expand the literature on the topic, there is still insufficient data on influential journals and article impact measures to guide researchers through journal submissions. This article aims to evaluate research productivity and identify influential journals and authors within the field. Utilizing bibliometric indices like impact factor, h-index, and eigenfactor will facilitate the assessment process.

Methods: A comprehensive search on July 1, 2023 in the Scopus database to identify articles related to pancreatic cancer. The search criteria included the keyword "Pancreatic Cancer" in the subject area of "Medicine", limited to English language articles published between January 1989 and December 2022. We calculated publication and citation counts at the article, journal, and first author levels, employing various measures of centrality. Statistical analysis was conducted using the Student t-test.

Results: The search yielded 52,154 articles from 3,155 journals with total citations of 1,903,916. The journal with the largest median citations dealing solely with pancreatic cancer was the Annals of Surgery. The journal with the highest number of publications is Pancreas. Six of the top twenty most cited articles were treatment-related articles. Of the top 30 journals by article count, JAMA had the highest median citation count, 340 of 33 articles. The most cited authors list was not associated with high productivity, similarly, the most productive authors were not associated with a high rate of citations.

Conclusions: This study offers valuable insights for researchers and institutions in guiding journal selections and themes identified as popular among the research community. It positively impacts the selection of appropriate journals to submit articles on the topic by easily identifying the most impactful and cited journals. The findings emphasize the growing interest in the field, the emergence of specialized journals, and a focus on treatment-related investigations. Overall, this analysis underscores the relevance of bibliometric approaches in advancing pancreatic cancer research.

Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030. This is driven by a high case-fatality rate with most patients even with radiologically localized PDAC at diagnosis ultimately relapsing with metastatic disease. KRAS mutations present in 90% to 95% of PDAC drive these poor statistics through its role in driving cellular growth, inhibition of apoptosis, and immunosuppression. The recent development of KRAS inhibitors has increased interest in understanding key molecular differences between the different KRAS codon changes seen in PDAC and other malignancies and how this might alter therapeutic decision making.

Methods: To understand how mutant KRAS influences the PDAC tumor microenvironment (TME) and cytokine signaling, we evaluated patients enrolled on NCT02451982 (A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients with Surgically Resectable Adenocarcinoma of the Pancreas). Interleukin 8 levels were measured using ELISA, these levels were compared with previously determined KRAS mutation status using next generation sequencing, tumor immune microenvironment populations quantified using multiplex immunohistochemistry, and survival outcomes.

Results: We identified a total of 30 patients from cohorts A: GVAX, an allogeneic whole cell cancer vaccine (n=16) and B: GVAX + anti-PD-1 (nivolumab) (n=14) with known KRAS mutation status and survival outcomes. Twenty-six of these tumors were KRAS mutant (G12C: 1, G12D: 11, G12R: 4, G12V: 10) and four were KRAS wild type. As KRAS G12D was the most commonly identified mutation and has been associated in some cohorts with worse outcomes, this was evaluated as a separate subgroup. KRAS G12D mutant PDAC had decreased disease-free survival (P=0.01) and a trend towards inferior overall survival in patients treated with GVAX alone (P=0.14) or GVAX plus anti-PD-1 (P=0.17) which became significant when combining both treatment groups (P=0.04). Looking at the relationship between KRAS status and the immune composition of the TME, patients with KRAS mutant PDAC had a trend towards decreased CD8⁺ T lymphocyte (P=0.06) following treatment with GVAX compared to KRAS wild type tumors. With the addition of anti-PD-1 in Arm B, patients with KRAS G12D mutant disease had a lower ratio of CD8⁺ GZMB⁺/CD8⁺ T lymphocytes (P=0.005).

Conclusions: KRAS G12D mutated PDAC represents a unique subtype of disease with decreased survival and lower ratio of activated CD8⁺ T lymphocytes as denoted by granzyme B (GZMB) positivity following GVAX/aPD-1 treatment.